Skip to content
Apollo Hospitals logo

Apollo Hospitals Enterprise

APOLLOHOSP NSE
₹9,200.00 +462.00 (+5.29%)
Market Cap
₹1,32,282 Cr
P/E
59.00
View as Markdown
MCP
Close 20 Nov 2026 ₹9,200.00 1Y +1,845.50 +25.1%
Start ₹7,354.50

Key Fundamentals

LargecapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.40%
Debt to Equity
0.77
EPS (TTM)
₹155.94
Book Value
₹737.49
Market Cap
₹1,32,282 Cr
P/E (TTM)
59.00
P/B
12.47
ROE
21.50%
Dividend Yield
0.23%
EBITDA
₹3,961 Cr
52W High
₹9,282.50
52W Low
₹6,696.50
Day Range
₹8,800.00 – ₹9,282.50
Volume
14,12,562

Peer Comparison

Healthcare › Healthcare Services › Hospital

Apollo Hospitals peer comparison
Apollo Hospitals (this company)
9,200.0059.001,32,28212.470.23%21.50%17.40%27,6302,337
1,081.0076.231,05,2159.280.20%14.70%14.70%9,1461,380
702.20101.7792,3666.010.00%6.72%8.30%12,370873
779.30110.7067,9298.720.41%11.30%11.60%6,508564
825.0059.9662,2845.940.13%11.20%13.40%9,9101,061
1,480.2064.3339,7989.200.03%15.20%17.40%5,053613
1,943.7046.2539,7227.940.24%20.50%15.50%10,273859
Median 7 companies1,081.0064.3367,9298.720.20%14.70%14.70%9,910873

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 100/100

Category scores

Quality
50
Average
Returns, margins, earnings quality 22% weight
Valuation
40
Weak
Cheap vs sector & own history 24% weight
Growth
56
Good
Sales & profit trajectory 9% weight
Financial Health
27
Poor
Solvency, leverage, coverage 9% weight
Momentum
24
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 76.8% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 17.7%

Weaknesses

2
  • Stock is trading at 12.5 times its book value
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4213
OscillatorsBearish423
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
70.74
Bearish
MACD (12,26,9)
185.51
Bullish
SMA (50)
8,384.71
Bullish
SMA (200)
8,212.45
Bullish

As of

Analyst Rating

Based on 27 analysts
BUY85%

23 of 27 analysts rate Buy, 3 Hold, 1 Sell.

As of

BUY
23
85%
HOLD
3
11%
SELL
1
4%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+15.16%
5Y+19.03%
3Y+14.94%
1Y+15.76%
TTM+19.35%

Net profit

Net profit growth by window
10Y+23.90%
5Y+71.00%
3Y+33.39%
1Y+33.09%
TTM+35.24%

Operating cash flow

Operating cash flow growth by window
10Y+16.94%
5Y+17.69%
3Y+27.53%
1Y+33.71%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+3.86 pp
5Y+4.18 pp
3Y+2.55 pp
1Y+1.06 pp
TTM+1.07 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹7,256 Cr
Mar 2018₹8,243 Cr
Mar 2019₹9,617 Cr
Mar 2020₹11,247 Cr
Mar 2021₹10,560 Cr
Mar 2022₹14,663 Cr
Mar 2023₹16,612 Cr
Mar 2024₹19,059 Cr
Mar 2025₹21,794 Cr
Mar 2026₹25,228 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹131 Cr
Mar 2018₹60.00 Cr
Mar 2019₹200 Cr
Mar 2020₹432 Cr
Mar 2021₹137 Cr
Mar 2022₹1,108 Cr
Mar 2023₹844 Cr
Mar 2024₹935 Cr
Mar 2025₹1,505 Cr
Mar 2026₹2,003 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,205 Cr −3.5% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk medium

Apollo Hospitals Enterprise Ltd trades at ₹8,738 as of 2026-11-19, commanding a market cap of ₹1,25,639 Cr with a P/E (TTM) of 56.03 and ROE of 20.08%. The company has demonstrated strong profit compounding at 77% CAGR over five years alongside 19% TTM sales growth, though the stock trades at 11.85 times book value and carries a debt-to-equity ratio of 0.9.

Bull Case 8
  • Exceptional five-year compounded profit growth of 77% CAGR reflects a sharp improvement in earnings power across hospital and digital health segments
  • TTM profit growth of 35% indicates continued strong momentum in the most recent period, well above the 10-year compounded profit growth rate of 24%
  • ROE of 20.08% as of 2026-11-19, with the last-year ROE at 21%, represents a meaningful step-up from the 10-year average ROE of 13%, signalling improved capital efficiency
  • Compounded sales growth of 19% on a TTM basis matches the five-year CAGR of 19%, suggesting revenue momentum has been sustained rather than front-loaded
  • Ten-year compounded sales growth of 15% demonstrates durable, long-term demand for the company's healthcare services across economic cycles
  • The stock has delivered a 10-year price CAGR of 22%, reflecting long-term wealth creation through both business growth and re-rating
  • The company has maintained a healthy dividend payout ratio of 17.7%, providing a degree of capital return discipline despite being in a growth phase
  • Trading at ₹8,738 against a 52-week low of ₹6,696.50, the stock has recovered roughly 30% from its annual trough, indicating resilient investor confidence
Bear Case 6
  • A trailing P/E of 56.03 is well above the broader market average, requiring sustained high earnings growth to justify the premium valuation
  • Debt-to-equity ratio of 0.9 is notable for a hospital business; combined with concerns that the company might be capitalising interest costs, the true leverage picture warrants scrutiny
  • Dividend yield of just 0.23% offers negligible income support, meaning returns depend almost entirely on capital appreciation
  • The three-year stock CAGR of 17% and five-year stock CAGR of 9% lag the 10-year CAGR of 22%, suggesting the pace of market re-rating may be decelerating
  • Three-year compounded sales growth of 15% has not accelerated versus the 10-year rate of 15%, indicating revenue growth may be approaching a steady state rather than inflecting higher
  • ROCE of 19.79% trails the ROE of 20.08% only marginally, but the gap could widen if debt-funded expansions do not generate proportionate returns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Apollo Hospitals delivered a strong Q2FY27 with 32% profit growth and 23% revenue expansion, reflecting robust demand across core specialties and international patient services. No notable headwinds emerged in the period's coverage. The growth trajectory remains firmly positive, though sustaining this pace will depend on continued volume momentum and margin discipline in coming quarters.

Positives 1
  • Q2FY27 PAT surges 32% YoY Nov 4

    Consolidated PAT rose 32% YoY to ₹630 crore in Q2FY27. Revenue grew 23% YoY to ₹7,615 crore, driven by strong volume growth in core specialties and international services.

Quarterly Results

₹ Cr
APOLLOHOSP quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
4,847
4,851
4,944
5,086
5,589
5,527
5,592
5,842
6,189
6,477
6,606
6,932
7,615
Expenses
4,219
4,237
4,303
4,410
4,774
4,765
4,822
4,990
5,264
5,512
5,594
5,855
6,424
Operating Profit
628
614
640
675
816
762
770
852
924
965
1,011
1,077
1,191
OPM %
13%
13%
13%
13%
15%
14%
14%
15%
15%
15%
15%
16%
16%
Other Income
26
29
37
49
44
69
72
54
54.7
48
54
52
58
Interest
111
113
119
116
118
110
115
108
99
113
119
108
114
Depreciation
163
167
190
177
184
185
211
215
205
219
224
222
230
PBT
379
363
368
430
557
536
516
583
675
682
722
799
904
Tax %
34%
30%
30%
27%
29%
29%
20%
24%
27%
24%
24%
24%
27%
Net Profit
249
254
258
316
396
379
414
441
494
516
551
610
660
EPS (₹)
16.20
17.06
17.65
21.23
26.34
25.89
27.10
30.10
33.19
34.93
36.81
40.39
43.81
YoY Sales growth
14
14
15
15
15
14
13
15
11
17
18
19
23

Profit & Loss

₹ Cr
APOLLOHOSP profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
5,129
6,150
7,256
8,243
9,617
11,247
10,560
14,663
16,612
19,059
21,794
25,228
27,630
Expenses
4,392
5,465
6,522
7,442
8,548
9,656
9,420
12,474
14,548
16,665
18,761
21,449
23,386
Operating Profit
737
684
734
801
1,070
1,591
1,140
2,189
2,065
2,394
3,033
3,779
4,244
OPM %
14%
11%
10%
10%
11%
14%
11%
15%
12%
13%
14%
15%
15%
Other Income
47
92
60
24
26
222
103
368
75
123
222
207
213
Interest
118
180
257
295
327
533
449
379
381
449
458
450
454
Depreciation
212
264
314
359
396
620
573
601
615
687
758
876
896
PBT
455
332
222
171
373
660
221
1,578
1,144
1,380
2,039
2,661
3,107
Tax %
29%
29%
41%
65%
47%
34%
38%
30%
22%
32%
26%
25%
—
Net Profit
335
235
131
60
200
432
137
1,108
844
935
1,505
2,003
2,338
EPS (₹)
24.43
16.99
15.88
8.44
16.96
32.70
10.46
73.42
56.97
62.50
100.56
135.04
155.94
Div. Payout %
24%
35%
38%
59%
35%
18%
29%
16%
26%
26%
13%
15%
—
Sales growth
18
20
18
14
17
17
−6
39
13
15
14
16
19

Balance Sheet

₹ Cr
APOLLOHOSP balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
70
70
70
70
70
70
72
72
72
72
72
72
72
Reserves
3,102
3,262
3,244
3,182
3,264
3,270
4,531
5,551
6,126
6,864
8,140
9,408
10,532
Borrowings
1,992
2,834
3,125
3,427
3,673
3,596
4,160
4,068
4,332
5,333
7,864
8,493
8,149
Other Liabilities
1,296
1,195
1,665
1,917
2,159
4,354
2,629
3,570
3,886
4,474
4,568
4,210
5,469
Total Liabilities
6,459
7,360
8,103
8,596
9,166
11,289
11,392
13,261
14,416
16,742
20,644
22,183
24,222
Fixed Assets
3,244
3,997
4,591
4,773
4,982
7,432
6,778
8,296
8,520
9,664
10,988
12,272
12,246
CWIP
533
562
347
712
822
236
234
46
610
873
921
1,032
1,494
Investments
311
352
406
352
462
434
1,343
816
574
986
2,487
2,179
2,192
Other Assets
2,372
2,448
2,759
2,759
2,901
3,187
3,037
4,104
4,712
5,219
6,248
6,700
8,291
Total Assets
6,459
7,360
8,103
8,596
9,166
11,289
11,392
13,261
14,416
16,742
20,644
22,183
24,222

Cash Flow

₹ Cr
APOLLOHOSP cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
470
597
623
537
905
1,293
1,265
1,696
1,377
1,920
2,136
2,856
Investing
−759
−888
−1,152
−405
−711
−289
−880
−747
−857
−1,537
−3,383
−2,145
Financing
392
330
477
−108
−215
−910
−340
−792
−633
−311
1,319
−478
Net Cash Flow
103
39
−52
24
−20
94
44
158
−113
72
73
233
Free Cash Flow
−396
−393
−46
−84
233
782
984
1,044
252
785
439
925
CFO/EBITDA
77
108
103
83
103
100
108
87
85
100
86
92

Ratios

APOLLOHOSP financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
43
36
38
37
39
33
46
44
49
48
51
50
Inventory Days
50
49
47
51
46
49
16
21
17
17
16
15
Days Payable
59
66
51
55
56
60
74
79
82
88
72
63
Cash Conversion Cycle
34
19
34
33
29
22
−12
−14
−16
−23
−6
3
Working Capital Days
24
16
27
8
−3
−8
−4
5
−1
−19
−6
−25
ROCE %
12%
9%
8%
7%
10%
14%
8%
17%
14%
15%
17%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Apollo Hospitals insights

64 extracted metrics across FY00–FY27.

Shareholding Pattern

As of Sep 2026

  • FIIs 43.18%
  • Promoters 28.02%
  • DIIs 22.07%
  • Public 4.46%
  • Others 2.03%
  • Government 0.23%

2.91% of promoter holding pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Apollo Hospitals Enterprise

What does Apollo Hospitals Enterprise Ltd do?
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country.
Where is Apollo Hospitals Enterprise Ltd (APOLLOHOSP) listed?
Apollo Hospitals Enterprise Ltd trades as APOLLOHOSP on the NSE and under code 508869 on the BSE.
Which sector does Apollo Hospitals Enterprise Ltd belong to?
Apollo Hospitals Enterprise Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd has a market capitalisation of ₹1,32,282 Cr as of 20 Nov 2026, which places it in the Largecap band.
What is the PE ratio of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd trades at a PE ratio of 59.00 as of 20 Nov 2026, on earnings per share of ₹155.94, against a book value of ₹737.49 per share.
What is the 52-week high and low of Apollo Hospitals Enterprise Ltd?
Over the last 52 weeks Apollo Hospitals Enterprise Ltd has traded between ₹6,696.5 and ₹9,282.5 as of 20 Nov 2026.
Does Apollo Hospitals Enterprise Ltd pay dividends?
Apollo Hospitals Enterprise Ltd has a dividend yield of 0.23%.
What is the Return on Equity (ROE) of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd reported a return on equity of 21.50%. Its debt-to-equity ratio is 0.77.

Company Information

Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country. Apollo Hospitals has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models.

CEO Dr. Prathap Chandra Reddy FCCP, FICA, FRCS, M.D., MBBS
Employees 42,497
Listed 10 Jan 1996
Face Value ₹5
Shares Outstanding 14,37,84,657

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APOLLOHOSP.md for Apollo Hospitals Enterprise Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More